The new funding will support the expansion of Evaro’s NHS-licensed digital healthcare infrastructure, enabling consumer brands to offer regulated online care and helping improve access to services amid pressure on primary care.
Evaro, an NHS-licensed digital healthcare platform, has closed a $25 million Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI.
Founded by medical professionals, the company provides embeddable prescribing and pharmacy infrastructure that enables consumer brands to offer regulated digital healthcare services directly to their customers. The platform supports treatment across more than 80 conditions and has served over two million patients to date, working with a range of consumer brands.
Evaro’s infrastructure includes asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare, and can be integrated into existing digital platforms within a short timeframe. For partners, the model enables the addition of healthcare services with limited implementation effort, while supporting new revenue streams and deeper customer engagement.
Dr Thuria Wenbar, CEO and co-founder of Evaro, explained that the company has developed infrastructure that allows trusted consumer brands to offer safe, regulated healthcare for common conditions without building their own systems.
The funding comes amid increasing pressure on primary care in the UK, driven by extended waiting times for GP appointments. Evaro aims to help address this demand by expanding access to regulated digital healthcare services.
Looking ahead, the company plans to broaden its reach and further develop its healthcare-as-a-service offering in the UK market.